Novan — Investor Presentation (April 2017)
39 slides from Novan's investor presentation, Apr 12, 2017
Slide 1: Corporate Presentation April 12, 2017
Corporate Presentation April 12, 2017 Exhibit 99.1
Slide 2: Forward-looking statements
This presentation includes forward-looking statements that reflect our current views with respect to, among other things, our operations and financial performance. These forward-looking statements are included throughout this presentation. We have used the words “anticipate,” “assume,” “believe,” “c
Slide 3: Overview
Technology platform for transforming nitric oxide into new chemical entities and product candidates for a host of skin diseases SB204 – Lead asset in Phase 3 clinical development Completed two Phase 3 pivotal trials in 1Q 2017 with SB204, 4% once-daily p<0.05 on all three co-primary endpoints in one
Slide 4: Experienced Leadership
Experienced Leadership Management Team Nathan Stasko, PhD Chief Executive Officer, Director William Hodges Interim Chief Financial Officer Brian Johnson, MBA Chief Commercial Officer M. Joyce Rico, MD, MBA Chief Medical Officer Paula Brown Stafford Chief Development Officer Stan Hollenbach, JD Senio
Slide 5: Our Nitric Oxide Pipeline
Our Nitric Oxide Pipeline Our focus on these five indications targets disease burden in >150M individuals in the US and >1.5B individuals globally. Product Candidates Indication Target Preclinical / Phase 1 Phase 2 Phase 3 Anticipated Milestones SB204 Acne Vulgaris P. acnes, IL-1, IL-17 Pre-NDA meet
Slide 6: Nitric Oxide Platform Overview
Nitric Oxide Platform Overview
Slide 7: Nitric Oxide Mechanisms of Action
Science – Breakthrough of the Year (1992) Nobel Prize in Medicine (1998) >100,000 peer reviewed manuscripts Broad Spectrum Antimicrobial Anti-bacterial Anti-viral Anti-fungal Immunomodulatory Agent Decreases key biomarkers for inflammation Inhibits T cell proliferation Results in NO-derived regulato
Slide 8: Nitricil Technology
Nitricil Technology Stable storage Drugable form of nitric oxide with shelf-life stability Therapeutic quantities High loading capacity previously unachievable “Tunability” pH-controlled hydrolysis that releases nitric oxide Engineered macromolecule Targets nitric oxide delivery to the skin Minimize
Slide 9: Formulation Science
Formulation Science Cosmetic Elegance FDA’s IID For Topical Use Irritation Potential Compatibility with Nitricil In vitro Release Shelf-life Stability Product Candidates (SB204) Nitricil based NCEs Our goal is to balance the need for safe and effective delivery of nitric oxide with physician and pat
Slide 10: Our Nitric Oxide Platform
Our Nitric Oxide Platform NVN1000 Nitric Oxide Proprietary chemistry that stores large amounts of nitric oxide in solid form Macromolecular NCEs Drug Candidates Indication specific formulations with differentiated nitric oxide release rates Formulation Science Nitricil Technology SB204 SB206 Over 10
Slide 11: Summary of Intellectual Property Portfolio
Summary of Intellectual Property Portfolio Covered Patent Life Issued Patents (Pending Applications) NitricilTM Technology Composition of Matter Family of Compounds – 8,282,967 NVN1000 Composition – 8,956,658 NVN4000 Composition – 8,962,029 Method of Manufacture to 2026 to 2032 US, Japan, Australia
Slide 12: SB204 Potential First-in-Class Topical for the Treatment of Acne
SB204 Potential First-in-Class Topical for the Treatment of Acne
Slide 13: Nitric Oxide and Acne
Nitric Oxide and Acne Hanna-Leena Kelhälä et al. IL-17/Th17 Pathway is Activated in Acne Lesions. PLoS One. 2014;9(8): e105238. Niedbala W et al. Regulation of Type 17 Helper T-Cell Function by Nitric Oxide During Inflammation Proc Natl Acad Sci USA. 2011;108(22):9220-9225. Niedbala W et al. Nitric
Slide 14: SB204
SB204 SB204 Activating Hydrogel NVN1000 Alcohol Gel SB204 is a once-daily, fast-acting, cosmetically elegant topical gel that has completed two Phase 3 pivotal trials for the treatment of acne vulgaris Potential first-in-class topical treatment that has shown evidence of efficacy against both inflam
Slide 15: Phase 3 Pivotal Trial Design
>2,600 patients enrolled in two, identical studies across 110 sites in the US 1:1 randomization, SB204, 4% once-daily vs. Vehicle once-daily 12 weeks of treatment Inclusion Criteria Ages 9 and up Minimum 20 and no more than 40 inflammatory lesions on the face Minimum 25 and no more than 70 non-infla
Slide 16: Patient Demographics and Disposition
Patient Demographics and Disposition SB204 NI-AC301 (n = 652) Vehicle gel NI-AC301 (n = 654) SB204 NI-AC302 (n = 663) Vehicle gel NI-AC302 (n = 664) Age, years Mean 21.1 21.3 21.4 21.8 Min to max 10 - 65 10 - 66 9 - 64 9 - 73 Gender Male 38.7% 37.9% 38.0% 40.1% Female 61.3% 62.1% 62.0% 59.9% Mean Le
Slide 17: Administration-Site and Other Treatment Emergent Adverse Events
Administration-Site and Other Treatment Emergent Adverse Events SB204 NI-AC301 Vehicle gel NI-AC301 SB204 NI-AC302 Vehicle gel NI-AC302 General Disorders and Administration-Site Conditions Pain 21 (3.2%) 3 (0.5%) 14 (2.1%) 4 (0.6%) Erythema 11 (1.7%) 1 (0.2%) 10 (1.5%) 2 (0.3%) Pruritus 16 (2.4%) 3
Slide 18: Phase 3 Cutaneous Tolerability Evaluations
SB204 Vehicle Week 2 Week 12 Week 2 Week 12 Mild Mod Severe Mild Mod Severe Mild Mod Severe Mild Mod Severe Erythema 24% 9% 0% 19% 4% <1% 19% 6% 0% 15% 3% <1% Scaling 14% 1% 0% 9% 1% 0% 8% <1% 0% 6% <1% <1% Dryness 20% 4% <1% 17% 2% <1% 17% 2% 0% 15% <1% <1% Itching 11% 2% 0% 8% 2% <1% 9% <1% 0% 7%
Slide 19: Phase 3 Top Line Results – Co-Primary Endpoints
Absolute changes in lesion count reduction are shown as LSMean *Intent-to-treat analysis. Missing data imputed using multiple imputation methodology. †In a modified ITT analysis excluding patients on oral contraceptive prescriptions with an acne indication, the absolute change in inflammatory lesion
Slide 20: Lesion Reduction for SB204 4% Once Daily
Lesion Reduction for SB204 4% Once Daily Inflammatory Lesions Weeks Mean percent change from baseline Non-Inflammatory Lesions Weeks Mean percent change from baseline Intent-to-treat population. NI-AC302 SB204, 4% QD NI-AC301 SB204, 4% QD Phase 2b SB204, 4% QD The onset of action by week 4 and the m
Slide 21: SB204 Program Target Timeline
Pre-Phase 3 TLR Post Phase 3 TLR Pre-NDA Meeting 3Q 2017 3Q 2017 NDA Submission 4Q 2017 1Q 2018 Approval and Launch 1H 2019 1H 2019 Ongoing Studies Long-Term Safety (NI-AC303) 3Q 2017 3Q 2017 2-Year Dermal Toxicology 4Q 2017 4Q 2017 Additional Clinical Studies* -- Additional Well-Controlled Trial Ad
Slide 22: SB206 Product Candidate for the Treatment of Viral Skin Infections
SB206 Product Candidate for the Treatment of Viral Skin Infections
Slide 23: Human Papilloma Virus (HPV) Associated Warts
Human Papilloma Virus (HPV) Associated Warts HPV affects nearly 80 million Americans 14 million people become infected each year Over 100 subtypes, low and high risk strains During 2013-2014, prevalence of any genital HPV was 42.5% among adults aged 18-591 45.2% among men and 39.9% among women Preva
Slide 24: HPV Associated Warts Market Opportunity
HPV Associated Warts Market Opportunity *WAC Dec 2016 QuintilesIMS NDTI A significant number of patients suffer from cutaneous HPV-related infections. High Pricing* for EGW treatments and favorable reimbursement given unmet need Aldara - $919 for 12 packets Zyclara - $1,037 for 28 packets Veregen -
Slide 25: Phase 2 Clinical Study of SB206
Phase 2 Clinical Study of SB206 12 week treatment duration SB206 4% gel 2x/day SB206 4% gel 1x/day Vehicle gel 1x/day SB206 8% gel 1x/day Primary endpoint Secondary endpoints include: Proportion of patients at week 12 who are completely clear of warts present at baseline Proportion of patients at we
Slide 26: Phase 2 Patient Demographics and Disposition
Phase 2 Patient Demographics and Disposition Vehicle gel QD/BID (n = 27) SB206 4% gel BID (n = 12) SB206 4% gel QD (n = 24) SB206 8% gel QD (n = 14) SB206 12% gel QD (n = 30) Gender, n (%) Male 19 (70.4%) 6 (50.0%) 16 (66.7%) 12 (85.7%) 23 (76.7%) Female 8 (29.6%) 6 (50.0%) 8 (33.3%) 2 (14.3%) 7 (23
Slide 27: Phase 2 Treatment-Emergent and Application-Site Adverse Events
Phase 2 Treatment-Emergent and Application-Site Adverse Events Vehicle gel QD/BID (n = 27) SB206 4% gel BID (n = 12) SB206 4% gel QD (n = 23) SB206 8% gel QD (n = 14) SB206 12% gel QD (n = 30) General Disorders and Administration-Site Conditions 1 (4.2%) 6 (50.0%) 6 (26.1%) 1 (7.1%) 5 (16.7%) Burn 0
Slide 28: Phase 2 Primary Endpoint Complete Clearance of Baseline Warts
Phase 2 Primary Endpoint Complete Clearance of Baseline Warts (ITT & PP analyses) p=0.0099 p=0.0200 Solid (ITT) Lined (PP)
Slide 29: SB208 Product Candidate for the Treatment of Onychomycosis
SB208 Product Candidate for the Treatment of Onychomycosis
Slide 30: Onychomycosis and Tinea Pedis Co-infection
Onychomycosis and Tinea Pedis Co-infection Causative agents for both diseases are primarily the dermatophytes T. rubrum, T. mentagrophytes, and E. floccosum. T. pedis (Athlete’s foot) occurs in at least 33% of onychomycosis patients Post hoc analysis from efinaconazole clinical trials showed higher
Slide 31: SB208 Single Topical Formulation for Onychomycosis and Tinea Pedis
SB208 is potentially the first product to target onychomycosis and tinea pedis with a single topical formulation As a gas, nitric oxide readily penetrates the nail plate reaching the site of infection2 1De Groote MA, et al. NO inhibitions: antimicrobial properties of nitric oxide. Clin Infect Dis. 1
Slide 32: Forecasted SB208 Development Program Endpoints
Forecasted SB208 Development Program Endpoints Endpoints Safety and tolerability Culture negativity Mycological cure defined as negative KOH and negative culture Therapeutic cure Safety and tolerability Mycological cure defined as negative KOH and negative culture Complete or almost complete cure de
Slide 33: SB208 Phase 2 Tinea Pedis Trial Design
220 patients enrolled in two sites in the Dominican Republic Randomized 1:1:1:1 SB208 Gel (2%, 4% or 16%) or vehicle treatment arms Treated once daily, 2 weeks of treatment with 4 week follow-up visit Inclusion Criteria Ages 18 and 70 Clinical diagnosis of tinea pedis on one or both feet localized t
Slide 34: SB208 Phase 2 Top Line Results
SB208 Phase 2 Top Line Results (mITT Population) mITT, subjects with evaluable culture result Primary Endpoint Negative Culture at Week 2 (Day 14) Secondary Endpoint Mycological Cure 4 Weeks Post Treatment (Day 42) p=0.002 p=0.016 (n=33) p=0.020 (n=31) (n=31) (n=31) (n=34) (n=34) (n=35) (n=34)
Slide 35: SB414 Product Candidate for the Treatment of Inflammatory Skin Diseases
SB414 Product Candidate for the Treatment of Inflammatory Skin Diseases
Slide 36: The NLRP3 Inflammasome & Inflammatory Skin Disease
The NLRP3 Inflammasome & Inflammatory Skin Disease Mishra B et al. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome–dependent processing of IL-1β. Nature Immunology. 2013;14:52-60. Niedbala W et al. Regulation of Type 17 Helper T-Cell Function by Nitric Oxid
Slide 37: Evidence of IL-17 Pathway Activation in Inflammatory Skin Disorders
Evidence of IL-17 Pathway Activation in Inflammatory Skin Disorders Th, T helper cell; Tc, IL-17-producing CD8+ T cell; Y, yes; L, likely, but some conflicting results; C, conflicting results. Skin Circulation Developmental Validation Th17 cells Tc17 cells Neutrophils IL-17+ cells IL-17 in serum/ pl
Slide 38: Potential Non-Steroidal Topical Treatment for Inflammatory Skin Disease
Potential Non-Steroidal Topical Treatment for Inflammatory Skin Disease Our intent is to develop SB414 for patients with psoriasis and atopic dermatitis who are not eligible for systemic therapy and who have limited non-steroidal, topical treatment choices. Key Findings Dose-dependent decreases in i
Slide 39: Upcoming Milestones
Upcoming Milestones SB204 (Acne vulgaris) SB206 (Anti-viral) SB208 (Anti-fungal) Targeted NDA Submission Report TLRs from long-term safety study Report TLRs from Phase 3 pivotal trials TLRs = Top line results Report TLRs from Phase 2 POC T. pedis trial Conduct EOP2 meeting with FDA Complete dermal s